While most investors will be extremely familiar with blue chip healthcare shares such as Ramsay Health Care Limited (ASX: RHC) and CSL Limited (ASX: CSL), there are a number of small-cap healthcare shares on ASX which are flying under the radar.
I think the three small-cap shares listed below are well worth getting better acquainted with. Here's why:
Medical Developments International Ltd (ASX: MVP)
I think this fast-growing healthcare company could have a very bright future thanks to the global expansion of its Penthrox pain management product. Management aims to make the green whistle product a mainstream analgesic of choice around the world and is well on its way to doing so. Over the next 12 months the company expects to have Penthrox approved for sale in more than 37 new countries around the world. I feel this is likely to lead to a significant lift in revenue over the next few years, which could make Medical Developments International a good buy and hold investment option.
National Veterinary Care Ltd (ASX: NVL)
I believe National Veterinary Care is in a strong position to deliver above-average earnings growth for the foreseeable future due to the high level of pet ownership in Australia and New Zealand and its growth through acquisition strategy. The company acquired and integrated 14 veterinary services businesses in FY 2017, including its first in New Zealand. This, along with its solid organic growth, helped lift full-year revenue by an impressive 51% to $66.9 million.
Zenitas Healthcare Ltd (ASX: ZNT)
I think this home care and health services company with 54 locations across Australia could be a big winner from Australia's ageing population. Zenitas has a wide range of community-based health services that provide integrated care solutions with the aim of reducing the high cost of acute hospital care. In FY 2017 the company delivered pro forma EBITDA of $7 million, up 27.3% on FY 2016 and 6.1% greater than its prospectus forecast. Pleasingly, management expects this strong growth to continue in FY 2018 and has provided guidance of EBITDA in the range of $13 million to $13.5 million.
